Literature DB >> 9207577

Endometriosis-associated pelvic pain: evidence for an association between the stage of disease and a history of chronic pelvic pain.

D W Stovall1, L M Bowser, D F Archer, D S Guzick.   

Abstract

OBJECTIVE: To track the severity and location of pelvic pain associated with endometriosis throughout the reproductive-age years and to evaluate the association between these pain parameters and the stage of disease.
DESIGN: Historical prospective study.
SETTING: Tertiary care center. PATIENT(S): Forty-eight women with endoscopically staged endometriosis and chronic pelvic pain who had undergone medical and/or conservative surgical therapy. INTERVENTION(S): Each participant was administered a questionnaire that included a determination of the severity and location of her pain. MAIN OUTCOME MEASURE(S): The stage of disease, the area of the pelvis that contained the bulk of disease, the severity of pain, and the location of the most severe pain were recorded. RESULT(S): The mean duration from the initial diagnosis until follow-up was 15.7 +/- 3.1 years, Twenty-one (43.8%) subjects denied any symptoms of pain on follow-up evaluation. Of the 27 patients with persistent pain, 21 (78%) identified the location of their most severe pain as being the same as at initial diagnosis. The stage of disease at initial diagnosis was significantly associated with a higher degree of pain at follow-up. CONCLUSION(S): These data suggest that endometriosis-associated chronic pelvic pain commonly persists throughout the reproductive years and that endometriosis stage is directly related to the persistence of pelvic pain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9207577     DOI: 10.1016/s0015-0282(97)81468-9

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

Review 1.  Endometriosis and nuclear receptors.

Authors:  Bahar D Yilmaz; Serdar E Bulun
Journal:  Hum Reprod Update       Date:  2019-07-01       Impact factor: 15.610

Review 2.  Current drug therapy recommendations for the treatment of endometriosis.

Authors:  A Bergqvist
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

3.  Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma.

Authors:  C Uzan; E Darai; A Valent; O Graesslin; A Cortez; R Rouzier; P Vielh
Journal:  Virchows Arch       Date:  2009-03-18       Impact factor: 4.064

4.  Eutopic endometrium and peritoneal, ovarian and bowel endometriotic tissues express a different profile of matrix metalloproteinases-2, -3 and -11, and of tissue inhibitor metalloproteinases-1 and -2.

Authors:  Catherine Uzan; Annie Cortez; Charlotte Dufournet; Raffaèle Fauvet; Jean-Pierre Siffroi; Emile Daraï
Journal:  Virchows Arch       Date:  2004-09-28       Impact factor: 4.064

5.  Expression of apoptosis-related proteins in endometriomas and benign and malignant ovarian tumours.

Authors:  Raffaèle Fauvet; Christophe Poncelet; Danièle Hugol; Anne Lavaur; Gérard Feldmann; Emile Daraï
Journal:  Virchows Arch       Date:  2003-05-20       Impact factor: 4.064

Review 6.  Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer.

Authors:  J Julie Kim; Takeshi Kurita; Serdar E Bulun
Journal:  Endocr Rev       Date:  2013-01-09       Impact factor: 19.871

7.  Genetic burden associated with varying degrees of disease severity in endometriosis.

Authors:  Yadav Sapkota; John Attia; Scott D Gordon; Anjali K Henders; Elizabeth G Holliday; Nilufer Rahmioglu; Stuart MacGregor; Nicholas G Martin; Mark McEvoy; Andrew P Morris; Rodney J Scott; Krina T Zondervan; Grant W Montgomery; Dale R Nyholt
Journal:  Mol Hum Reprod       Date:  2015-04-16       Impact factor: 4.025

8.  Evaluation of Risk Factors Associated with Endometriosis in Infertile Women.

Authors:  Mahnaz Ashrafi; Shahideh Jahanian Sadatmahalleh; Mohammad Reza Akhoond; Mehrak Talebi
Journal:  Int J Fertil Steril       Date:  2016-04-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.